Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
Condition: Healthy Volunteers (Meningococcal Infection) Interventions: Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine (MenACYW conjugate vaccine); Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®); Biological: Diphtheria, Tetanus, Acellular Pe rtussis, Poliovirus and Haemophilus b Vaccine; Biological: Pneumococcal 13-valent Conjugate Vaccine; Biological: Rotavirus Vaccine; Biological: Hepatitis B Vaccine; Biological: Measles, Mumps, and Rubella Virus Vaccine; Biological: Varicella Virus Vaccine Sponsor: Sanofi Pasteur, a Sanofi Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: ActHIB | Diphtheria | Measles | Measles Vaccine | Men | Meningitis | Meningitis Vaccine | Mumps | Mumps Vaccine | Pediatrics | Pneomococcal Vaccine | Rubella | Rubella Vaccine | Tetanus | Tetanus Vaccine | Vaccines